Unital Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 03-01-2025
- Paid Up Capital ₹ 10.00 K
as on 03-01-2025
- Company Age 3 Year, 4 Months
- Last Filing with ROC 31 Mar 2022
About Unital Pharmaceuticals
The Company is engaged in the Food And Beverages Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 10.00 K , as per Ministry of Corporate Affairs (MCA) records.
Ravi Chandrashekarapuram and Rajiv Mishra serve as directors at the Company.
- CIN/LLPIN
U24304CH2021PTC043908
- Company No.
043908
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Sep 2021
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Unital Pharmaceuticals Private Limited offer?
Unital Pharmaceuticals Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antibacterial Drugs, Common Disease Medicines, Anti-Itch Skin Cream, Pharmaceutical Capsules, Pain Relief Drugs & Pharmaceuticals, Aceclofenac, Allopathic Cough Syrup, Antifungal Cream, Ointment & Powder, Nutraceuticals & Dietary Supplements.
Who are the key members and board of directors at Unital Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravi Chandrashekarapuram  | Director | 28-Apr-2023 | Current |
| Rajiv Mishra | Director | 22-Aug-2024 | Current |
Financial Performance of Unital Pharmaceuticals.
Enhance accessibility to Unital Pharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Unital Pharmaceuticals?
Unlock access to Unital Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Unital Pharmaceuticals?
Unital Pharmaceuticals has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unital Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unital Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
